923288-95-3Relevant articles and documents
Method for preparing nilotinib monohydrochloride dihydrate crystal form A
-
Paragraph 0133-0162, (2021/08/07)
The invention provides a method for preparing nilotinib monohydrochloride dihydrate crystal form A. Specifically, the method provided by the invention comprises the following steps: (1) mixing nilotinib a free alkali as shown in a formula I, hydrochloric
KINASE INHIBITOR SALTS AND COMPOSITIONS THEREOF
-
Page/Page column 91-92, (2020/01/08)
The present invention relates to kinase inhibitor C8-C16 aliphatic sulfate salts and compositions thereof.
PROCESS FOR THE PREPARATION OF PURE NILOTINIB AND ITS SALT
-
Paragraph 0139; 0140, (2018/12/04)
Object of the present invention is a process for the preparation of the pharmaceutical active ingredient Nilotinib free base or Nilotinib dihydrochloride dihydrate by means of an improved crystallization procedure.